Get our lovely INSIGHT 2019 conference news


Email address
First Name
Last Name
Interested in InSight 2019
Cart
<We_can_help/>

What are you looking for?

<Good_things_happen/> Welcome to Conference

Therapeutic Mechanisms of Psychedelic Drugs: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression

Poster

Psilocybin has shown promise as a treatment for depression but its therapeutic mechanisms are not properly understood. In contrast to the presumed action of antidepressants, we recently found increased right amygdala responsiveness to fearful faces one day after treatment with psilocybin in 19 patients with treatment-resistant depression (TRD), which correlated with treatment efficacy. This was interpreted as regained emotional responsiveness post-treatment.
AIMS: The present study constitutes an extension to this basic activation analysis. We hypothesized changes in amygdala functional connectivity during emotional face processing after treatment with psilocybin. More precisely, we predicted that decreased functional connectivity between the amygdala and ventromedial prefrontal cortex (vmPFC) may underlie the previously observed increase in amygdala responsivity.
METHODS: Psychophysiological interaction analyses were conducted on functional Magnetic Resonance Imaging (fMRI) data from a classic face/emotion perception task, with the bilateral amygdala and vmPFC time-series as physiological regressors.
RESULTS: Results showed decreased vmPFC-right amygdala functional connectivity during face processing post- (versus pre-) treatment, and this was associated with levels of rumination at one week. This effect was driven by connectivity changes in response to fearful and neutral (but not happy) faces. Independent whole-brain analyses also revealed a post-treatment increase in functional connectivity between the amygdala and vmPFC to occipital-parietal cortices during face processing.
CONCLUSION: These results are consistent with the idea that psilocybin therapy revives emotional responsiveness on a neural and psychological level – which may be a key treatment mechanism for psychedelic therapy. Future placebo-controlled studies are needed to examine the replicability of the current findings.

Speaker

Date

September 5th 2019

Time

tba

Location

tba
tickets
Lea Julia Mertens
M.Sc.

Lea Julia Mertens

Department of Molecular Neuroimaging, Central Institute of Mental Health, Mannheim more about the speaker

Related Events

The Psychedelic Altered State of Consciousness: Entropic brain theory vs. Integrated information theory

Classic psychedelic substances, such as lysergic acid diethylamide (LSD) and the active compound in magic mushrooms psilocybin, are being studied again in a renaissance of psychedelic research. Psychedelic substances have profound effects on the quality of subjective experience, as well as the capacity to induce mystical-type experiences and ego-dissolution. Recent clinical studies indicate that the subjective experiences from these substances have positive effects on patient populations and healthy participants, both acutely and long-term. Considering the therapeutic potency of the psychedelic-induced […]

more details

Acute effects of lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine in healthy subjects and in patients during drug-assisted psychotherapy

The aim of the study was to characterize and compare the acute subjective effects of LSD and MDMA in healthy subjects and in patients with psychiatric disorders in different settings. Acute effects of LSD and MDMA were investigated  in placebo-controlled, double-blind, cross-over studies in a laboratory setting in a total of 40 and 194 healthy subjects, respectively. Acute effects of 200 mcg LSD were assessed in 11 patients suffering from anxiety associated with a life-threatening disease, treated alone within a […]

more details

Psilocybin-Assisted Treatment of Alcohol Use Disorder: Historical Context and Current Clinical Research

The use of classic psychedelics in the treatment of alcohol use disorder dates to Hoffer and Osmond’s work with LSD in Saskatchewan starting in 1953. Initially seen as a way to safely induce a delirium tremens-like experience, LSD was tested in clinical trials and used in treatment programs for thousands of patients through the early 1970s, resulting in substantial but inconclusive evidence for its effectiveness. With increasing restriction of access to psychedelics for reach purposes, LSD research ceased in the […]

more details

Conference tickets

With your ticket you will have access to the whole conference - with keynotes, panels, round tables, posters and daylight social events. We will ask for a small extra fee for the Friday evening social program. The pre-conference workshops have to be booked separately and each workshop needs an individual ticket. By clicking on "Book now" below you also have the option to buy your workshop tickets.

*Reduced fees apply to students, cooperation partners as well as unemployed and retired individuals who have a monthly net income below 840,- €. Proof of status will be required.

THE CONFERENCE IS SOLD OUT! Subscribe to our newsletter to become an early bird for 2021!
https://mind-foundation.org/

Catering service

 

With this ticket you can use the catering service all inclusive for three days. The service includes coffee, water, tea and fruit.

Regular

after 14 April 2019

  • Standard €250
  • Reduced €150*
  • MIND members Standard €180
  • MIND members Reduced €90

Philanthropist

 

  • Donate €600 or more
  • Invite a friend/colleague to be your VIP guest at the event

Get our lovely INSIGHT 2019 conference news


Email address
First Name
Last Name